NAUT experienced a severe 55% cash burn with declining assets and equity, while simultaneously shifting from ambitious "revolutionary" messaging to more measured scientific positioning.
The dramatic cash depletion from $27.6M to $12.4M raises immediate liquidity concerns for this development-stage biotech company. While operating cash flow improved slightly, the current burn rate suggests potential funding needs within the next 12-18 months, creating dilution risk for shareholders.
NAUT's financials show a company under significant cash pressure, with cash and equivalents plummeting 55% to just $12.4M while total assets declined 21% and stockholders' equity fell 25%. The modest improvements in operating cash flow (-14%) and net loss (+17%) are overshadowed by the severe liquidity deterioration and reduced R&D spending (-19%), suggesting the company is cutting costs to preserve runway. Despite moving to Nasdaq Capital Market, the overall financial picture signals a development-stage biotech facing potential funding pressures in the near term.
Cash declined 55.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Capex reduced 39.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Equity decreased 24.8% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 21.3% — asset sales, write-downs, or balance sheet optimization underway.
Current assets declined 20.2% — monitor working capital adequacy and short-term liquidity.
R&D spending cut 18.6% — could signal cost discipline or concerning reduction in innovation investment.
Net income grew 16.6% — bottom-line growth signals improving overall business health.
Operating cash flow grew 14.3% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →